{"id":143489,"date":"2026-08-11T04:36:14","date_gmt":"2026-08-11T04:36:14","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/143489\/"},"modified":"2026-08-11T04:36:14","modified_gmt":"2026-08-11T04:36:14","slug":"eli-lilly-vs-novo-nordisk-has-glp-1-manufacturing-become-the-new-competitive-moat","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/143489\/","title":{"rendered":"Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?"},"content":{"rendered":"\n

The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY<\/a>) and Novo Nordisk (NYSE:NVO<\/a>) compete for dominance in one of healthcare’s fastest-growing markets. <\/p>\n

Yet another competitive advantage for investors to keep in mind is manufacturing. <\/p>\n

During the early stages of the GLP-1 boom, demand consistently exceeded supply. Shortages of Wegovy, Ozempic, Mounjaro, and Zepbound demonstrated that developing a breakthrough medicine is only part of the challenge. Companies must also manufacture those medicines reliably, expand production fast enough to meet demand, and build enough capacity to support the next generation of therapies. <\/p>\n

That raises an important question for investors. As the obesity market matures, will the competitive advantage belong to the company with the strongest drugs, or the one with the strongest manufacturing platform? <\/p>\n

\"\"<\/a> <\/p>\n

A specialized research team in white lab coats working together on a breakthrough biotechnological discovery. <\/p>\n

Bull Case <\/p>\n

Eli Lilly (NYSE:LLY) increasingly appears to view manufacturing as a long-term competitive advantage rather than simply a production necessity. Over the past several years, the company has committed tens of billions of dollars to expanding its manufacturing footprint across the United States. Rather than concentrating on a single facility, Lilly (NYSE:LLY) is investing across multiple manufacturing technologies, including active pharmaceutical ingredients, injectable medicines, and advanced therapies. This broader approach could give the company flexibility not only to support current demand for Mounjaro and Zepbound but also to manufacture future pipeline assets as they reach commercialization. <\/p>\n

That flexibility may become increasingly valuable. Today’s obesity market is dominated by injectable therapies, but Lilly’s (NYSE:LLY) pipeline extends well beyond its current products. Building capacity across multiple technologies today reduces the likelihood that manufacturing becomes a bottleneck tomorrow. The strategy also creates optionality beyond obesity. Manufacturing assets developed for peptide medicines, biologics, and advanced therapies can potentially support a much broader pharmaceutical portfolio. In other words, Lilly (NYSE:LLY) is investing in infrastructure that could generate value long after today’s GLP-1 supply constraints disappear. <\/p>\n

Story Continues <\/p>\n

Lilly’s (NYSE:LLY) manufacturing strategy also reflects a broader shift in how pharmaceutical companies think about competitive advantage. Historically, manufacturing was viewed as a support function that followed successful drug development. In the obesity market, however, manufacturing capacity has become a prerequisite for commercial success. The companies capable of supplying enough medicine can continue gaining market share, while those constrained by production risk leave demand unmet regardless of clinical performance. <\/p>\n

Novo Nordisk’s (NYSE:NVO) strategy is different but no less compelling. Novo has continued expanding a production network that already includes decades of expertise in peptide manufacturing. The company has invested heavily in expanding its Clayton, North Carolina campus while strengthening its fill-finish capabilities through the acquisition of former Catalent facilities. Since three decades, the company has expanded nine times in North Carolina, invested nearly $6 billion dollars, built and upgraded two more facilities, and expanded its employee count from 50 to more than 2,000. <\/p>\n

In addition to expanding its U.S. footprint, the company’s manufacturing network remains more geographically diversified than Lilly’s (NYSE:LLY), which has historically been an advantage from an operational perspective. This approach also emphasizes manufacturing experience rather than manufacturing scale alone. Producing complex biologic medicines consistently and efficiently requires years of operational knowledge, and Novo remains one of the world’s largest manufacturers of insulin and GLP-1 therapies. <\/p>\n

Bear Case <\/p>\n

The biggest risk for Lilly (NYSE:LLY) is that manufacturing capacity eventually becomes abundant rather than scarce. Extraordinary demand for obesity medicines is one of the factors driving increased investment in its operations, but the competitive landscape is evolving rapidly. Novo Nordisk (NYSE:NVO) continues expanding production, while several other pharmaceutical companies are developing competing obesity therapies. If supply eventually catches up with demand, manufacturing capacity may become less of a competitive differentiator and more of a fixed cost. That would place greater pressure on Lilly (NYSE:LLY) to generate attractive returns from one of the largest manufacturing expansion programs in the pharmaceutical industry. <\/p>\n

Novo Nordisk (NYSE:NVO) faces a different challenge. While the company possesses extensive manufacturing expertise, it has also experienced periods where demand outpaced available supply. Those shortages suggested that operational excellence alone cannot overcome insufficient production capacity. As the obesity market continues expanding, Novo Nordisk (NYSE:NVO) should continue expanding its manufacturing capacity quickly enough to support future prescription growth without supply constraints. <\/p>\n

There is also a strategic question surrounding manufacturing flexibility. Lilly’s (NYSE:LLY) broader investments across multiple production technologies may ultimately provide greater optionality if obesity treatments evolve toward new drug modalities or if future pipeline assets require different manufacturing processes. Novo’s (NYSE:NVO) existing manufacturing network could prove highly efficient for current products, and could work in the future as well if it remains adaptable to the industry’s manufacturing requirements that may change significantly over the next decade. <\/p>\n

Which Manufacturing Strategy Is Better? <\/p>\n

The comparison ultimately reflects two different philosophies. Lilly (NYSE:LLY) is investing aggressively today to build manufacturing capacity that can support both current demand and future innovation. The strategy requires substantial capital but could create a durable competitive advantage if demand remains strong and the company’s pipeline continues delivering new products. <\/p>\n

Novo Nordisk (NYSE:NVO) is relying on decades of manufacturing expertise while expanding capacity where it sees the greatest need. That approach requires less capital and may ultimately produce higher returns if future demand grows more gradually than many investors expect. <\/p>\n

Neither approach is inherently superior. Their success will ultimately depend on whether future demand justifies Lilly’s (NYSE:LLY)\u00a0 aggressive investment or rewards Novo’s (NYSE:NVO) more measured expansion strategy. <\/p>\n

Conclusion <\/p>\n

The next stage of competition between Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) may be determined as much by manufacturing execution as by scientific innovation. Clinical leadership remains essential, but blockbuster medicines create value only when companies can consistently manufacture enough product to meet demand. The shortages experienced throughout the GLP-1 market demonstrated that manufacturing is no longer simply an operational issue but rather a strategic differentiator. <\/p>\n

Lilly (NTSE:LLY) appears better positioned if manufacturing scale becomes the defining competitive advantage. Its aggressive investment program provides significant flexibility for future pipeline assets while reducing the risk that production capacity limits growth. Novo Nordisk (NYSE:NVO), however, should not be underestimated. Its decades of manufacturing expertise, expanding global production network, and disciplined capital allocation provide a different path toward the same objective. <\/p>\n

For investors, the real question is no longer which company can develop the next breakthrough obesity medicine. It is which company can build the manufacturing platform capable of supporting the next decade of obesity treatment. <\/p>\n

While we acknowledge the potential of NVO and LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the <\/a>best short-term AI stock<\/a>. <\/p>\n

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years<\/a> AND 12 Best Stocks That Will Always Grow<\/a>.\u00a0 <\/p>\n

Disclosure: None.\u00a0Follow Insider Monkey on Google News<\/a>. <\/p>\n","protected":false},"excerpt":{"rendered":"The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have…\n","protected":false},"author":2,"featured_media":143490,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[68602,276,2073,272,357],"class_list":["post-143489","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-competitive-advantage","tag-eli-lilly","tag-manufacturing","tag-novo-nordisk","tag-obesity"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117075023392543687","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/143489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=143489"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/143489\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/143490"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=143489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=143489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=143489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}